Research output per year
Research output per year
Fingerprint
Dive into the research topics where Sunghoon Kim is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Anti-apoptotic Splicing Variant of AIMP2 Recover Mutant SOD1-Induced Neuronal Cell Death
Kook, M. G., Byun, M. R., Lee, S. M., Lee, M. H., Lee, D. H., Lee, H. B., Lee, E. J., Baek, K., Kim, S., Kang, K. S. & Choi, J. W., 2023 Jan, In: Molecular Neurobiology. 60, 1, p. 145-159 15 p.Research output: Contribution to journal › Article › peer-review
1 Citation (Scopus) -
Synthesis and discovery of the first potent proteolysis targeting chimaera (PROTAC) degrader of AIMP2-DX2 as a lung cancer drug
Lee, B. R., Kim, D. G., Lee, A., Kim, Y. M., Cui, L., Kim, S. & Choi, I., 2023, In: Journal of Enzyme Inhibition and Medicinal Chemistry. 38, 1, p. 51-66 16 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus) -
Tryptophan-dependent and -independent secretions of tryptophanyl- tRNA synthetase mediate innate inflammatory responses
Nguyen, T. T. T., Choi, Y. H., Lee, W. K., Ji, Y., Chun, E., Kim, Y. H., Lee, J. E., Jung, H. S., Suh, J. H., Kim, S. & Jin, M., 2023 Jan 31, In: Cell Reports. 42, 1, 111905.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus) -
AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis
Kim, D. G., Choi, Y., Lee, Y., Lim, S., Kong, J., Song, J. H., Roh, Y., Harmalkar, D. S., Lee, K., Goo, J. I., Cho, H. Y., Mushtaq, A. U., Lee, J., Park, S. H., Kim, D., Min, B. S., Lee, K. Y., Jeon, Y. H., Lee, S., Lee, K., & 1 others, 2022 Dec, In: Nature communications. 13, 1, 2572.Research output: Contribution to journal › Article › peer-review
Open Access3 Citations (Scopus) -
Author Correction: O-GlcNAc modification of leucyl-tRNA synthetase 1 integrates leucine and glucose availability to regulate mTORC1 and the metabolic fate of leucine (Nature Communications, (2022), 13, 1, (2904), 10.1038/s41467-022-30696-8)
Kim, K., Yoo, H. C., Kim, B. G., Kim, S., Sung, Y., Yoon, I., Yu, Y. C., Park, S. J., Kim, J. H., Myung, K., Hwang, K. Y., Kim, S. & Han, J. M., 2022 Dec, In: Nature communications. 13, 1, 6253.Research output: Contribution to journal › Comment/debate › peer-review
Open Access
Press/Media
-
Daewoong Pharmaceutical Publishes Molecular Mechanism Of Bersiporocin As An Antifibrotic In EMBO Molecular Medicine
23/5/25
1 item of Media coverage
Press/Media: Press / Media
-
Medicinal Bioconvergence Res Center and Industry Academic Cooperation Foundation Yonsei Univ Obtain Patent for Compound as Mtor Inhibitor and Use Thereof
23/5/18
1 item of Media coverage
Press/Media: Press / Media